Search research articles
Contact Us
Filters
Showing results (121-130 of 212) with videos related to
Page
of 22
Sort By:
British Journal of Haematology
|
October 14, 2009
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia
Thomas R Chauncey, Holly Gundacker, Mazyar Shadman, et al.
Leukemia Research Reports
|
June 6, 2022
Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning
David A Sallman, Rafael Bejar, Guillermo Montalban-Bravo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia
Eric J Feldman, Jeffrey E Lancet, Jonathan E Kolitz, et al.
Leukemia Research
|
November 27, 2010
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens
Samantha L Price, Jeffrey E Lancet, Timothy J George, et al.
British Journal of Haematology
|
January 24, 2018
Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes
Kathy L McGraw, Johnny Nguyen, Najla H Al Ali, et al.
Blood
|
July 20, 2007
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
Azim Mohamedali, Joop Gäken, Natalie A Twine, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 5, 2019
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes
Rami S Komrokji, Sheng Wei, Adam W Mailloux, et al.
Haematologica
|
February 4, 2014
A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction
Rami S Komrokji, Adam W Mailloux, Dung-Tsa Chen, et al.
Leukemia Research
|
September 3, 2013
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
Deepa Sampath, Asifa Malik, William Plunkett, et al.
Haematologica
|
March 6, 2016
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
Gregory A Abel, Fabio Efficace, Rena J Buckstein, et al.
Page
of 22
Search research articles
Search
Showing results (121-130 of 212) with videos related to
Sort By:
Page
of 22
British Journal of Haematology
|
October 14, 2009
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia
Thomas R Chauncey, Holly Gundacker, Mazyar Shadman, et al.
Leukemia Research Reports
|
June 6, 2022
Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning
David A Sallman, Rafael Bejar, Guillermo Montalban-Bravo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia
Eric J Feldman, Jeffrey E Lancet, Jonathan E Kolitz, et al.
Leukemia Research
|
November 27, 2010
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens
Samantha L Price, Jeffrey E Lancet, Timothy J George, et al.
British Journal of Haematology
|
January 24, 2018
Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes
Kathy L McGraw, Johnny Nguyen, Najla H Al Ali, et al.
Blood
|
July 20, 2007
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
Azim Mohamedali, Joop Gäken, Natalie A Twine, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 5, 2019
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes
Rami S Komrokji, Sheng Wei, Adam W Mailloux, et al.
Haematologica
|
February 4, 2014
A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction
Rami S Komrokji, Adam W Mailloux, Dung-Tsa Chen, et al.
Leukemia Research
|
September 3, 2013
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
Deepa Sampath, Asifa Malik, William Plunkett, et al.
Haematologica
|
March 6, 2016
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
Gregory A Abel, Fabio Efficace, Rena J Buckstein, et al.
Page
of 22